Concentrations of lonazolac in serum and synovial fluid of patients with inflammatory or degenerate joint disease.
In 15 patients with inflammatory and degenerative joint disease the concentrations of lonazolac were measured in serum and synovial fluid at steady state conditions. The mean concentration in the synovial fluid in 14 patients was 0.275 microgram/ml, which was 48% of that in the serum. For the patients with inflammatory joint disease, the synovial fluid concentration of lonazolac was 61% of that in the serum whereas in degenerative joint disease it reached only 39%.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000378:metabolism* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000378:metabolism* / Q000627:therapeutic use; D013582:Synovial Fluid / Q000378:metabolism*
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; C017472:lonazolac